Loading
The PD-1 antibody nivolumab produced responses in about seven in ten patients whose Hodgkin lymphoma had returned after a stem cell transplant, with responses lasting well over a year, confirming the exquisite sensitivity of this lymphoma to checkpoint blockade.
Multicohort single-arm phase 2 study of 243 patients with classical Hodgkin lymphoma relapsed or refractory after autologous stem cell transplantation, treated with nivolumab; cohorts were brentuximab-naive, brentuximab after transplant, and brentuximab before and/or after transplant.
With extended follow-up the objective response rate was 69 percent, median duration of response 16.6 months and median progression-free survival 14.7 months; responses were independent of PD-L1 expression level, and the safety profile matched other nivolumab studies. The data underpinned regulatory approval of nivolumab in this setting.
Nivolumab, like pembrolizumab, is a standard for relapsed Hodgkin lymphoma after transplant, and the activity seen here led to its testing in first-line therapy (S1826).
Shares CheckMate 205, Chemotherapy-free Hodgkin lymphoma: brentuximab + PD-1 in early stage.
Shares CheckMate 205, Nivolumab.
Shares Relapsed and refractory classical Hodgkin lymphoma, Journal of Clinical Oncology.
Shares Chemotherapy-free Hodgkin lymphoma: brentuximab + PD-1 in early stage, Nivolumab.
Shares Chemotherapy-free Hodgkin lymphoma: brentuximab + PD-1 in early stage, Relapsed and refractory classical Hodgkin lymphoma.
Shares Relapsed and refractory classical Hodgkin lymphoma, Nivolumab.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/